Drugs.com New Drug ApplicationsOriginal article
CeleCor Completes Submission of FDA New Drug Application for Investigational Heart-Attack Drug
NDA FilingzalunfibanPositive
AI Analysis
Summary
CeleCor Therapeutics has completed submission of its New Drug Application to the FDA for zalunfiban, an investigational heart-attack drug. The submission represents a regulatory milestone in the drug's development pathway.
Outcome Details
Final section of New Drug Application submitted to FDA
Importance:6/10
Sentiment:
0.60
cardiovascularFDA submissioninvestigational drug
Read the original article
Published by Drugs.com New Drug Applications on June 24, 2026 9:06 PM